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Summary
Objectives: A strong association of cytokines [interleukin (IL)-6, IL-2 and tumor
necrosis factor (TNF)-] with atherosclerosis is well documented. However, their
role in Chlamydia pneumoniae (Cp)-associated progression of coronary artery dis-
ease (CAD) is not well studied. Hence we evaluated the presence of these cytokines
in CAD patients positive for Cp immunoglobulin (Ig) A (low, medium, and high levels)
CAD and compared with controls. Also the physiological and baseline characteristics
in IL-6 positive CAD patients were studied.
Methods: During the period from March 2005 to June 2007, 192 CAD patients and
controls attending the cardiology clinic of Safdarjung Hospital, New Delhi, India were
enrolled. ELISA was performed for the estimation of Cp IgA, high sensitive C-reactive
protein (hsCRP), and cytokines IL-6, IL-2, and TNF- in CAD patients and controls.
Results: IL-6 was signiﬁcantly higher in CAD patents with medium and higher Cp
IgA levels (35 vs. 10 and 32 vs. 4) compared to controls. Physiological features and
baseline characteristics of CAD were signiﬁcantly higher in IL-6 positive CAD patients.
Additionally, in CAD patients IL-6 was signiﬁcantly correlated with hsCRP (p < 0.001,
r = 0.42).
Conclusions: Our results lead us to hypothesize the role of IL-6 in the pathogenesis
of CAD, which may subsequently get accelerated through Cp infection.
© 2008 Japanese College of
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lhlamydia pneumoniae and coronary artery disease
o its rapidly increasing prevalence in developing
ountries [1]. Apart from known conventional risk
actors such as dyslepidemia, diabetes, hyperten-
ion, and sedentary life style, a strong association
f inﬂammation and cytokines with atherosclerosis
s documented [2,3]. There is strong evidence sup-
orting the central role of interleukin (IL)-6 in the
nﬂammatory response as it is the primary determi-
ant of C-reactive protein (CRP) which is reported
o be one of the most powerful independent risk
actors for coronary heart disease (CHD) [4—6]. In
ddition, bacterial pathogens in particular Chlamy-
ia pneumoniae (Cp) are reported to be potent
nducers of IL-6, which may induce plaque produc-
ion and subsequently may cause elevation in serum
RP and IL-6 levels [7,8]. Moreover, IL-2 a pro-
nﬂammatory cytokine secreted by T-helper type 1
Th1) lymphocytes has been correlated with various
ardiovascular disorders [9].
However, the exact involvement of tumor necro-
is factor (TNF)- levels, a potent inﬂammatory
ytokine and IL-2 in the pathophysiology of cardiac
isorders are still undeﬁned [10—12]. Since Cp IgA is
eported to be a prevalent marker for CAD patients
n India [13,14], we evaluated the cytokines IL-6,
L-2, and TNF- in CAD patients positive for Cp
gA with low, medium, and high levels as it will
elp in understanding the chronicity of CAD in
ndia. In addition, taking IL-6 as a marker in CAD
atients, baseline and physiological characteristic
ere compared with controls in order to elucidate
ts signiﬁcance in disease progression. Further to
stablish IL-6 as an independent atherosclerotic
arker, we evaluated the correlation between lev-
ls of IL-6 and high sensitive (hs)CRP, and levels of
L-6 and IL-2 in CAD patients as well as in controls.
aterials and methods
atients
total of 192 patients (148 males and 44 females)
ttending the cardiology out patient department
f Safdarjung hospital from March 2005 to June
007 for suspected CAD and subsequently admitted
or angioplasty were enrolled for the study after
rior written consent. In addition, 192 age- and sex-
atched healthy controls with no evidence of CAD
142 males and 50 females) were also included in
he study. The study received clearance from the
ospital ethics review committee.
Inclusion criteria: Evidence of CAD required at
east one of the following: (1) signiﬁcant stenosis
70% of luminal diameter) in at least one major
n
s
v
o
l141
oronary artery proved by angiography and had
ndertaken either percutaneous coronary interven-
ion or coronary artery bypass graft (CABG); (2)
ositive stress myocardial perfusion imaging studies
or ischemia.
Exclusion criteria: Patients were not included
f any of the following were present: myocardial
nfarction or CABG in the preceding 3 months;
nstable angina; signiﬁcant valvular heart disease;
lood pressure 180/100mm. A detailed question-
aire was prepared to gather necessary information
rom each patient that included hemoglobin, heart
ate, blood pressure, blood sugar, blood urea,
otal leukocyte count (TLC), smoking habit, alcohol
ntake habit, lifestyle, migration, socio-economic
tatus, food habit, and number of previous heart
ttacks, if any.
ollection of samples
enous blood (2mL) was collected in non-
eparinized tubes from CAD patients and controls.
erum was separated within 2 h of blood collection
nd kept at −80 ◦C until used further for detec-
ion of antibodies to Cp-IgA, hsCRP, IL-6, IL-2, and
NF-.
erology and antibody level of
therosclerotic marker
etection of antibodies for Cp-speciﬁc IgA was
erformed using commercially available ELISA kit
R-Biopharm AG, Damstadt, Germany) [13]. We
ivided the samples into three groups based on
p IgA index number, low (1.1—1.6), medium
1.7—2.1), and high (more than 2.1). For detection
f antibodies to hsCRP, ELISA was performed using
its (Calibiotech Inc., USA) as per manufacturer’s
nstructions. Level of the hsCRP (>3mg/L) in serum
as considered as hsCRP positive in dichotomized
esult.
The cytokines IL-6, IL-2, and TNF-  were mea-
ured by commercial kit from (Ebiosciences, San
iego, CA, USA) as per manufacturer’s instructions.
tatistical analysis
PSS version 12.0 for Windows (SPSS Inc., Chicago,
L, USA) was used for statistical analysis. All sero-
ogical results were dichotomized as positive or
egative. For comparing diagnostic assays, chi-
quare test, Fisher-exact for binary a related
ariable was used. Simultaneously, an alpha level
f 0.05 was set as the level of signiﬁcance. Binary
ogistic regression was used to evaluate physiologi-
142
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al and baseline characteristics of CAD. Spearman’s
orrelation and t-test was used for the evaluation
etween hsCRP and IL-6 as well as IL-6 and IL-2 in
atients and healthy controls.
esults
lassiﬁcation of IgA seropositivity in hsCRP
nd pro-inﬂammatory cytokines (IL-2, IL-6,
nd TNF-) groups
n the group with low Cp-IgA index value consist-
ng of 37 CAD patients and 22 controls, positivity
or hsCRP (16 vs. 6, respectively) was signiﬁcantly
igher (p = 0.001) in CAD patients compared to con-
rols, however there was no signiﬁcant difference
or IL-6 (16 vs. 8, respectively), IL-2 (6 vs. 2, respec-
ively), and TNF- (4 vs. 1, respectively). In the
econd group with medium IgA index value (61 CAD
atients and 36 controls) positivity for hsCRP (43
s. 7, respectively) and IL-6 (35 vs. 10, respec-
ively) was signiﬁcantly higher (p < 0.001 and 0.006)
n CAD patients compared to controls, however dif-
erences were not signiﬁcant for IL-2 (15 vs. 6,
espectively) and TNF- (12 vs. 5, respectively).
imilarly in the third group with high IgA index
alue (57 CAD patients and 18 controls) positivity
or hsCRP (34 vs. 6, respectively) and IL-6 (32 vs. 4,
espectively) was signiﬁcantly higher (p < 0.001 and
.011) in CAD patients compared to controls, how-
ver differences were not signiﬁcant for IL-2 (8 vs.
, respectively) and TNF- (6 vs. 3, respectively)
Table 1).
aseline and physiological characteristics of
AD patients and controls on the basis of
L-6 positivity
total of 192 CAD patients and 192 controls
ere divided on the basis of IL-6 positivity under
ifferent physiological and baseline characteristics
Table 2). Some physiological features such as
eart rate, systolic and diastolic blood pressure,
lood sugar, blood urea, and TLC of IL-6 positive
AD patients were signiﬁcantly higher compared
o IL-6 positive controls. However, hemoglobin was
igniﬁcantly lower in IL-6 positive CAD patients
han IL-6 positive controls. Similarly in smokers,
on-smokers, alcoholic, non-alcoholic, normal
nd sedentary lifestyle, migrant and non-migrant
L-6 positive CAD patients was signiﬁcantly higher
ompared to IL-6 positive controls. Additionally,
L-6 positive CAD patients were found to be sig-
iﬁcantly higher in medium socioeconomic status
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Table 2 Comparison of baseline and physiological characteristic among IL-6 positive CAD patients and controls
Physiological characteristic Patient mean (±S.D.) Control mean (±S.D.) P value
Hemoglobin (gm/dL) 11.78 ± 2.24 12.5 ± 2.64 <0.001*
Heart rate (beats/min) 78 ± 8 74 ± 5 <0.001*
Systolic blood pressure (mm Hg) 137 ± 22 126 ± 15 <0.001*
Diastolic blood pressure (mm Hg) 90 ± 14 84 ± 9 <0.001*
Blood sugar (mmol/L) 132 ± 22 108 ± 18 <0.001*
Blood urea (mmol/L) 30 ± 12 26 ± 8 <0.001*
TLC (104 cells/L) 7870 ± 1370 7450 ± 1240 0.002*
Baseline characteristic Patient Control P value
Smoker (%) 80 (48.5) 30 (34) 0.029*
Non-smoker (%) 26 (42.6) 09 (12.8) <0.001*
Alcoholic (%) 44 (48.3) 20 (19.6) <0.001*
Non-alcoholic (%) 52 (52) 30 (33.3) 0.010*
Normal LS (%) 39 (52) 22 (23.1) <0.001*
Sedentary LS (%) 56 (47.8) 28 (31.8) 0.001*
Migrant (%) 85 (60.7) 36 (40.9) <0.001*
Non-migrant (%) 37 (44.5) 15 (20.2) 0.001*
LSES (%) 27 (48.2) 08 (29.6) 0.048*
MSES (%) 51 (50.5) 22 (21.7) <0.001*
18 (30) 0.027*
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Figure 1 (a) Correlation between IL-6 and hsCRP in CADHSES (%) 16 (50)
* Signiﬁcant, percentages in parenthesis.
MSES) (p < 0.001), low socioeconomic status (LSES),
nd high socioeconomic status (HSES) (p = 0.048 and
.027, respectively) as compared to controls. Food
abit viz. vegetarian and non-vegetarian was not
igniﬁcant between IL-6 positive CAD patients and
ontrols in our study (data not shown). Number of
eart attacks was also not signiﬁcantly different in
L-6 positive CAD patients as compared to controls
data not shown).
orrelation analysis
positive and signiﬁcant correlation (p < 0.001,
= 0.424) was found between hsCRP and IL-6 in CAD
atients (Fig. 1a). However, the correlation was not
igniﬁcant between IL-6 and IL-2 in CAD patients
p = 0.084, r = 0.158) (Fig. 2a). In healthy controls,
o signiﬁcant correlation (p = 0.995, r =−0.001)
as found between hsCRP and IL-6 and for IL-6
nd IL-2 (p = 0.404, r = 0.076) (Figs. 1 and 2(b),
espectively).
iscussion
AD contributes signiﬁcantly to morbidity and mor-
ality, particularly in developing countries like India
15]. The role of various immuno-inﬂammatory
ediators such as cytokines in the pathogenesis of
therosclerosis is gaining importance since these
ytokines have a role in triggering the perpetua-
patients. X-axis, levels of hsCRP (mg/L) in CAD patients.
Y-axis, levels of IL-6 (pg/mL) in CAD patients. (b) Corre-
lation between IL-6 and hsCRP in healthy controls. X-axis,
levels of hsCRP (mg/L) in healthy controls. Y-axis, levels
of IL-6 (pg/mL) in healthy controls.
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Figure 2 (a) Correlation between IL-6 and IL-2 in CAD
patients. X-axis, levels of IL-6 (pg/mL) in CAD patients.
Y-axis, levels of IL-2 (pg/mL) in CAD patients. (b) Corre-
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Rlation between IL-6 and IL-2 in healthy controls. X-axis,
levels of IL-6 (pg/mL) in healthy controls. Y-axis, levels
of IL-2 (pg/mL) in healthy controls.
tion of atherosclerosis and are potent inducers of
reactive free radicals, which can facilitate oxida-
tion of Low Density Lipoprotein, a key event in the
pathogenesis of atherosclerosis [16]. Our study for
the ﬁrst time revealed that positivity for IL-6 was
higher in CAD patients with medium and high Cp IgA
positivity suggesting these groups of patients may
have more chronic disease condition [17]. Kato et
al. also suggested that elevated IgA antibody to Cp
was a sign of a chronic and still active infection
of a past exposure [18]. Further a putative rela-
tionship between IL-6 levels and Cp IgA titers has
also been reported [19—21]. In vitro studies have
shown that acellular components of Cp can directly
stimulate IL-6 production in human blood mononu-
clear cells [20] and also elicits IL-6 production from
human smooth muscle cells [21]. It is therefore
likely that chronic Cp infection, in part, may inﬂu-
ence circulating IL-6 levels [18]. Other investigators
reported that elevation of IL-6 as an independent
risk factor for future myocardial infarction among
apparently healthy subjects [22—24]. These ﬁnd-
ings suggest a putative role of IL-6 for the initiation
and progression of atherosclerosis. In our study, IL-
2 and TNF- were not signiﬁcantly detected in all
the three groups. It is reported that soluble TNFH.C. Jha et al.
eceptor levels may act as a better marker for
therosclerotic burden than TNF- [25,26] and the
echanism behind the role of IL-2 in atherosclerosis
s still undeﬁned [9]. In addition, positivity for IL-
was detected to be signiﬁcantly higher in groups
ith physiological and baseline characteristics of
AD showing thereby that IL-6 can serve as a marker
or prognosis of CAD in Indian population also. In our
tudy, a positive correlation was observed for levels
f IL-6 and hsCRP in CAD patients; however IL-6 was
ot correlated with IL-2 in CAD patients. As earlier
tudies have shown that hsCRP is one of the most
owerful markers for predicting CHD [5,6], hence it
an be suggested that IL-6 can also serve as an inde-
endent atherosclerotic marker. Overall our data
trongly suggest the role of IL-6 in the pathogene-
is of CAD which may subsequently get accelerated
hrough Cp infection.
onﬂict of interest
one.
cknowledgments
he authors wish to thank Mr. Yogendra Kumar
nd Mrs. Madhu Badhwar for providing techni-
al assistance. University Grant Commission is
cknowledged for providing ﬁnancial assistance to
em Chandra Jha in the form of fellowship. The
tudy was funded by Department of Science and
echnology, SR/SO/HS-6/2005, India.
eferences
[1] Hansson GK, Robertson AL, Söderberg-Nauclér C. Inﬂamma-
tion and atherosclerosis. Annu Rev Pathol 2006;1:297—329.
[2] Bhatheja R, Bhatt DL. Clinical outcomes in metabolic syn-
drome. J Cardiovasc Nurs 2006;21:298—305.
[3] Sertic J, Slavicek J, Bozina N, Malenica B, Kes P, Reiner
Z. Cytokines and growth factors in mostly atherosclerotic
patients on hemodialysis determined by biochip array tech-
nology. Clin Chem Lab Med 2007;45:1347—52.
[4] Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics
of inﬂammation and risk of coronary artery disease: the
central role of interleukin-6. Eur Heart J 2000;21:1574—83.
[5] Haddy N, Sass C, Droesch S, Zaiou M, Siest G, Ponthieux
A, et al. IL-6, TNF- and atherosclerosis risk indicators
in a healthy family population: the STANISLAS cohort.
Atherosclerosis 2003;170:277—83.[6] Ablij HC, Meinders AE. C-reactive protein: history and
revival. Eur J Intern Med 2002;13:412—22.
[7] Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, Saikku P,
Linnavuori K, Leinonen M. Growth of Chlamydia pneu-
moniae in cultured human peripheral blood mononuclear
C[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[hlamydia pneumoniae and coronary artery disease
cells and induction of a cytokine response. Microb Pathog
1996;21:215—21.
[8] Claiborne JS, Hui Z, Louis MM, Michael LT, Deborah D.
Chlamydia pneumoniae burden in carotid arteries is associ-
ated with upregulation of plaque interleukin-6 and elevated
C-reactive protein in serum. Arterioscler Thromb Vasc Biol
2005;25:2648—53.
[9] Mizia-Stec K, Gasior Z, Zahorska-Markiewicz B, Janowska J,
Szulc A, Jastrzebska-Maj E, et al. Serum tumour necrosis
factor-[alpha], interleukin-2 and interleukin-10 activation
in stable angina and acute coronary syndromes. Coron
Artery Dis 2003;14:431—8.
10] Tedqui A, Mallat Z. Cytokines in atherosclerosis: pathogenic
and regulatory pathways. Physiol Rev 2006;86:515—
81.
11] Brånén L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson
J, Jovinge S. Inhibition of tumor necrosis factor- reduces
atherosclerosis in apolipoprotein E knockout mice. Arte-
rioscler Thromb Vasc Biol 2004;24:2137—42.
12] Pasqui AL, Renzo MD, Bova G, Maffei S, Pompella G, Auteri
A, et al. Pro-inﬂammatory/anti-inﬂammatory cytokine
imbalance in acute coronary syndromes. Clin Exp Med
2006;6:38—44.
13] Jha HC, Vardhan H, Gupta R, Verma R, Prasad J, Mittal A.
Higher incidence of chronic persistent infection of Chlamy-
dia pneumoniae in coronary artery disease in India is a cause
of concern. BMC Infect Dis 2007;7:48.
14] Jha HC, Prasad J, Mittal A. High IgA seropositivity for com-
bined Chlamydia pneumoniae, helicobacter pylori infection
and high sensitive C-reactive protein in coronary artery dis-
ease patients in India can serve as atherosclerotic marker.
Heart Vessels, doi:10.1007/s00380-008-1062-9, in press.
15] Dholpuria R, Raja S, Gupta BK, Chahar CK, Panwar RB, Gupta
R, et al. Atherosclerotic risk factors in adolescents. Indian
J Pediatr 2007;74:823—6.
16] Tesfamariam B, DeFelice AF. Endothelial injury in the initia-
tion and progression of vascular disorders. Vascul Pharmacol
2007;46:229—37.
17] Liu R, Yamamoto M, Moroi M, Kubota T, Ono T, Funatsu A,
et al. Chlamydia pneumoniae immunoreactivity in coronary
artery plaques of patients with acute coronary syndromes
[
Available online at www.145
and its relation with serology. Am Heart J 2005;150:
681—8.
18] Kato A, Odamaki M, Takita T, Maruyama Y, Kumagai
H, Hishida A. Association between interleukin-6 and
carotid atherosclerosis in hemodialysis patients. Kidney Int
2002;61:1143—52.
19] Mazzoli S, Tofani N, Semplici F, Salvi A, Fantini A, Bandini F,
et al. Chlamydia pneumoniae antibody response in patients
with acute myocardial infarction and their follow-up. Am
Heart J 1998;135:15—20.
20] Netea1 MG, Selzman CH, Kullberg BJ, Galama JMD, Wein-
berg A, Stalenhoef AFH, et al. Acellular components
of Chlamydia pneumoniae stimulate cytokine produc-
tion in human blood mononuclear cells. Eur J Immunol
2000;30:541—9.
21] Del JR, Woytas M, Groh A, Schmidt K, Hartmann M, Lehmann
M, et al. Production of basic ﬁbroblast growth factor
and interleukin 6 by human smooth muscle cells follow-
ing infection with Chlamydia pneumoniae. Infect Immun
2000;68:3635—41.
22] Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S,
Ettinger WH, et al. Associations of elevated interlukin-6 and
C-reactive protein levels with mortality in the elderly. Am
J Med 1999;106:506—12.
23] Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma
concentration of interleukin-6 and the risk of the future
myocardial infarction among apparently healthy men. Cir-
culation 2000;101:1767—72.
24] Yavuz MT, Yavuz O, Yazici M, Guler S, Ozhan H, Albayrak S,
et al. Interaction between Chlamydia pneumoniae seropos-
itivity, inﬂammation and risk factors for atherosclerosis in
patients with severe coronary stenosis. Scan J Clin Lab
Invest 2006;66:523—34.
25] Blann AD, McCollum CN. Increased levels of soluble tumor
necrosis factor receptors in atherosclerosis: no clear rela-
tionship with levels of tumor necrosis factor. Inﬂammation
1998;22:483—91.
26] Elkind MS, Cheng J, Boden-Albala B, Rundek T, Thomas
J, Chen H, et al. Tumor necrosis factor receptor lev-
els are associated with carotid atherosclerosis. Stroke
2002;33:31—8.
sciencedirect.com
